Daxor to Exhibit at the American Association of Heart Failure Nurses 2018 Advanced Heart Failure Symposium
March 22 2018 - 9:00AM
Daxor Corporation (
NYSE MKT: DXR), an investment
company with medical instrumentation and biotechnology operations,
announces it will exhibit for the first time at the American
Association of Heart Failure Nurses Advanced Heart Failure
Symposium, a medical education and medical technology exhibition
held on March 23th and 24th in Philadelphia, PA.
The two-day symposium will serve to educate registered nurses
and nurse practitioners about the latest advances in treatment
recommendations and therapeutic and diagnostic technologies for
advanced heart failure patients.
Daxor CEO Michael Feldschuh stated, “We are excited for two days
of focused meetings with leaders in the area of advanced heart
failure. Our participation in this exhibition is a direct response
to a trend we have noticed in recent years towards holistic care
teams composed of specialist and generalist clinicians, including
and often managed by heart failure coordinator RNs and NPs. Being
on the front line of a very difficult disease, these nurses are
often best positioned to understand the positive impact Daxor’s
precision blood volume analysis test has on patient care and
outcomes.”
Per its website the AAHFN is an organization “dedicated to
advancing nursing education, clinical practice and research to
improve heart failure patient outcomes” with the “goal of setting
the standards for heart failure nursing care.” The organization has
held a meeting annually since 2004.
Forward-Looking Statements
Certain statements in this release may include forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including without limitation, statements
regarding the impact of hiring sales staff and expansion of our
distribution channels. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this release, including, without
limitation, those risk associated with our post-market clinical
data collection activities, benefits of our products to patients,
our expectations with respect to product development and
commercialization efforts, our ability to increase market and
physician acceptance of our products, potentially competitive
product offerings, intellectual property protection, FDA regulatory
actions, our ability to integrate acquired businesses, our
expectations regarding anticipated synergies with and benefits from
acquired businesses, and additional other risks and uncertainties
described in our filings with the SEC. Forward-looking
statements speak only as of the date when made. Daxor does not
assume any obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact Information:
Daxor Corporation: Soren Thompson @ 212-330-8502 (Investor Relations) sthompson@daxor.com
Daxor (AMEX:DXR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Daxor (AMEX:DXR)
Historical Stock Chart
From Sep 2023 to Sep 2024